PCR Journal Club

Examination of the study methodology and results according to the PICOT principle, SWOT analysis and real-world applicability of the EBC MAIN trial presented at EuroPCR 2021.

The value of elective coronary revascularisation plus medical therapy over medical therapy alone in managing stable patients with coronary artery disease is debated. Hence, the authors reviewed all trials comparing the two strategies in this population to appraise whether revascularisation in addition to medical therapy affects...

This is a prespecified secondary sub-analysis of the TWILIGHT trial that seeks to shed light on the association of the different baseline risk factors, namely advanced age and significant renal dysfunction, with a higher bleeding risk in women.

ISCHEMIA-CKD is the only contemporary randomized trial that prospectively evaluated an upfront strategy of coronary angiography and revascularization plus optimal medical therapy (OMT) compared with OMT alone in patients listed for renal transplant.

This investigator-initiated randomised, open-label, multicentre trial compares FFR versus angiography guided strategies for treating non-culprit lesions in patients presenting with STEMI and multivessel coronary artery disease. The results of this study were released during ACC.21.

Using patient-level data from the Disrupt CAD I, II, III and IV trials, this pooled analysis assesses the efficacy and safety of intravascular lithotripsy in de novo calcified coronary lesions.

The current analysis aimed to compare the safety and efficacy of the Edwards Sapien S3 and Medtronic Corevalve. Furthermore, conscious sedation (CS) and local anaesthesia have been reported to reduce adverse events compared to general anaesthesia (GA) in several observational studies, with a lack of randomised...

The PIONEER III trial aims to assess the effectiveness and safety of the biodegradable-polymer sirolimus-eluting Supreme stent compared to durable-polymer everolimus-eluting stent (Xience or Promus), completely releasing the drug by 120 days.

In the PARTNER II trial, a new staging system of extra-aortic valvular cardiac damage is proposed, using 2 D transthoracic echocardiography and its prognostic value. The purpose of this study is to evaluate the prognostic value of such extra-aortic cardiac damage using MDCT in patients undergoing...

The aim of the current study was to determine the clinical characteristics, management and outcomes of STEMI after TAVR.